Health and Healthcare

Amgen : AMGN

All Amgen Articles

699 Articles

Jon C. Ogg | Jan 28, 2014 at 4:13 PM EST

Amgen Nails Earnings, Guidance a Different Story

ThinkstockAmgen Inc. (NASDAQ: AMGN) is the second largest biotech player, and now we have seen its fourth-quarter earnings report. Earnings…

Trey Thoelcke | Jan 22, 2014 at 9:05 AM EST

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Here are some of the top biotech names to buy at Cowen. They presented such an extensive list that we…

Trey Thoelcke | Dec 19, 2013 at 8:30 AM EST

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.

Jon C. Ogg | Nov 21, 2013 at 7:55 AM EST

Eight Big Dividend Hikes Expected Before 2013 Ends

ThinkstockInvestors love dividends, particularly safe and dependable dividends that rise through time. The S&P 500 Index currently has the most…

Jon C. Ogg | Nov 19, 2013 at 11:50 AM EST

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

ThinkstockThe market for pharmaceuticals and biotech drugs just keeps growing. The so-called patent cliff may be affecting Big Pharma companies…

Lee Jackson | Nov 14, 2013 at 9:30 AM EST

Five Prime Takeover Candidates for 2014

ThinkstockMany Wall Street analysts and strategists are forecasting a rise in corporate earnings for the rest of the year and…

Lee Jackson | Nov 6, 2013 at 8:30 AM EST

UBS Sees Hedge Funds Selling Health Care and Buying Financial and Energy Stocks

ThinkstockThe UBS proprietary institutional flow data indicates that hedge funds are increasing exposure to financials and decreasing exposure to health…

Jon C. Ogg | Oct 21, 2013 at 11:10 AM EDT

The Top 14 Earnings to Watch This Week

Jon OggThe S&P 500 Index is hitting all-time highs and we are now deep into earnings season. This week will…

Trey Thoelcke | Oct 14, 2013 at 8:15 AM EDT

Jefferies Top Biotech Stocks to Buy

ThinkstockThe world of biotechnology investing is a constantly evolving and changing one. While disease for the most part does not…

Jon C. Ogg | Oct 8, 2013 at 2:47 PM EDT

Market Take: Biotech Suffers Under Government Shutdown Too!

ThinkstockThe field of pharmaceuticals is very well established and often is considered to be a very defensive sector. As such,…

Lee Jackson | Oct 3, 2013 at 11:50 AM EDT

Top Biotechs Set to Win in the War on Cancer

ThinkstockTuesday saw the wrap up of the 2013 European Society of Medical Oncology (ESMO) conference in Amsterdam, which featured key…

Lee Jackson | Sep 4, 2013 at 8:25 AM EDT

UBS Picks Large Cap Biotechnology Stocks to Outperform the Rest of 2013

ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive…

Jon C. Ogg | Aug 26, 2013 at 1:29 PM EDT

Will Attorney Investigations or Class Action Suits Put Amgen-Onyx Buyout at Risk?

Jon OggAny time you see a merger announcement, you see a myriad of press releases pertaining to law firms and…

Jon C. Ogg | Aug 26, 2013 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: 3D, Hasbro, Dollar Tree, Tyson and More

Jon OggThis will be an interesting week for Wall Street analyst coverage as many traders, investors and analysts are out…

Jon C. Ogg | Aug 26, 2013 at 8:05 AM EDT

Lessons of Buying Growth Companies Doubling Their Revenues

ThinkstockAmgen Inc. (NASDAQ: AMGN) wants to regain its status as the largest publicly traded biotech in the U.S. The company formalized…

1 … 30 31 32 33 34 … 47

Amgen : AMGN

All Amgen Articles

Amgen Nails Earnings, Guidance a Different Story

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Eight Big Dividend Hikes Expected Before 2013 Ends

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

Five Prime Takeover Candidates for 2014

UBS Sees Hedge Funds Selling Health Care and Buying Financial and Energy Stocks

The Top 14 Earnings to Watch This Week

Jefferies Top Biotech Stocks to Buy

Market Take: Biotech Suffers Under Government Shutdown Too!

Top Biotechs Set to Win in the War on Cancer

UBS Picks Large Cap Biotechnology Stocks to Outperform the Rest of 2013

Will Attorney Investigations or Class Action Suits Put Amgen-Onyx Buyout at Risk?

Top Analyst Upgrades and Downgrades: 3D, Hasbro, Dollar Tree, Tyson and More

Lessons of Buying Growth Companies Doubling Their Revenues

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Amgen : AMGN

All Amgen Articles

Amgen Nails Earnings, Guidance a Different Story

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Eight Big Dividend Hikes Expected Before 2013 Ends

The $1 Trillion Drug Market Offers Great but Selective Growth in the Next Five Years

Five Prime Takeover Candidates for 2014

UBS Sees Hedge Funds Selling Health Care and Buying Financial and Energy Stocks

The Top 14 Earnings to Watch This Week

Jefferies Top Biotech Stocks to Buy

Market Take: Biotech Suffers Under Government Shutdown Too!

Top Biotechs Set to Win in the War on Cancer

UBS Picks Large Cap Biotechnology Stocks to Outperform the Rest of 2013

Will Attorney Investigations or Class Action Suits Put Amgen-Onyx Buyout at Risk?

Top Analyst Upgrades and Downgrades: 3D, Hasbro, Dollar Tree, Tyson and More

Lessons of Buying Growth Companies Doubling Their Revenues

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%